CD19 and Burkitt lymphoma: Remarkably, the combination of rapamycin-resistant anti-CD19 CAR T cells with rapamycin led to enhanced in vitro cytotoxicity against B cell ALL and Burkitt’s lymphoma cell lines compared to rapamycin monotherapy or treatment with conventional anti-CD19 CAR T cells [104].